Connect public, paid and private patent data with Google Patents Public Datasets

In-situ gel formation of pectins

Info

Publication number
CA2439570A1
CA2439570A1 CA 2439570 CA2439570A CA2439570A1 CA 2439570 A1 CA2439570 A1 CA 2439570A1 CA 2439570 CA2439570 CA 2439570 CA 2439570 A CA2439570 A CA 2439570A CA 2439570 A1 CA2439570 A1 CA 2439570A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
composition
comprises
method
substance
pectic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2439570
Other languages
French (fr)
Other versions
CA2439570C (en )
Inventor
Yawei Ni
Kenneth M. Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carrington Laboratories Inc
Original Assignee
Carrington Laboratories, Inc.
Yawei Ni
Kenneth M. Yates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

In-situ gelation of a pectic substance. Composition, method of preparation, and method of use of a pectin in-situ gelling formulation for the delivery and sustained release of a physiologically active agent to the body of an animal.
The pectin can be isolated from Aloe vera.

Claims (75)

1. A composition for the sustained release of a physiologically active agent in an animal, the composition comprising:
the physiologically active agent; and a pectic substance in an amount effective to gel in situ in the animal.
2. The composition of claim 1 further comprising a carrier.
3. The composition of claim 2, wherein the carrier comprises water, saline, buffered aqueous solution, oil/water emulsion, adjuvant, tablets, or capsules.
4. The composition of claims 1, wherein the pectic substance comprises a calcium-reactive pectin.
5. The composition of claim 1, wherein the pectic substance comprises a low methoxyl pectin.
6. The composition of claim 1, wherein the pectic substance comprises a polygalacturonic acid.
7. The composition of claim 1, wherein the pectic substance comprises an Aloe pectin.
8. The composition of claim 1 further comprising a monovalent cation.
9. The composition of claim 1 further comprising a sodium salt.
10. The composition of claim 2, wherein the composition has a pH from about 2 to about 10.
11. The composition of claim 1 further comprising a thickener.
12. The composition of claim 11, wherein the thickener comprises CMC, HPMC, collagen, gelatin, dextran, hyaluronic acid, or alginate.
13. The composition of claim 1, wherein the physiologically active agent comprises a pharmacologically active substance, a therapeutic agent, a diagnostic agent, a peptide, a nucleic acid, or a protein.
14. The composition of claim 1, wherein, based on the total weight of the composition, the physiologically active agent ranges from about 0.01 % to about 90 %.
15. A composition for the sustained release of a physiologically active agent in an animal, the composition comprising:
the physiologically active agent;
a carrier;
a pectic substance in an amount effective to gel in situ in the animal.
16. The composition of claim 15, wherein the carrier comprises water, saline, buffered aqueous solution, oil/water emulsion, adjuvant, tablets, or capsules.
17. The composition of claim 15, wherein the pectic substance comprises a calcium-reactive pectin.
18. The composition of claim 15, wherein the pectic substance comprises a low methoxyl pectin.
19. The composition of claim 15, wherein the pectic substance comprises a polygalacturonic acid.
20. The composition of claim 15, wherein the pectic substance comprises an Aloe pectin.
21. The composition of claim 15 further comprising a monovalent cation.
22. The composition of claim 15 further comprising a sodium salt.
23. The composition of claim 15, wherein the composition has a pH from about 2 to about 10.
24. The composition of claim 15 further comprising a thickener.
25. The composition of claim 24, wherein the thickener comprises CMC, HPMC, collagen, gelatin, dextran, hyaluronic acid, or alginate.
26. The composition of claim 15, wherein the physiologically active agent comprises a pharmacologically active substance, a therapeutic agent, a diagnostic agent, a peptide, a nucleic acid, or a protein.
27. A composition for the sustained release of a physiologically active agent in an animal, the composition comprising:
the physiologically active agent;
a carrier;
an Aloe pectic substance in an amount effective to gel in situ in the animal.
28. The composition of claim 27, wherein the carrier comprises water, saline, buffered aqueous solution, oil/water emulsion, adjuvant, tablets, or capsules.
29. The composition of claim 27, wherein the pectic substance comprises a calcium-reactive pectin.
30. The composition of claim 27, wherein the Aloe pectic substance comprises a low methoxyl pectin or a polygalacturonic acid.
31. The composition of claim 27 further comprising a monovalent cation.
32. The composition of claim 27 further comprising a sodium salt.
33. The composition of claim 27, wherein the composition has a pH of from about 2 to about 10.
34. The composition of claim 27 further comprising a thickener.
35. The composition of claim 34, wherein the thickener comprises CMC, HPMC, collagen, gelatin, dextran, hyaluronic acid, or alginate.
36. The composition of claim 27, wherein the physiologically active agent comprises a pharmacologically active substance, a therapeutic agent, a diagnostic agent, a peptide, a nucleic acid, or a protein.
37. A method for preparing a composition for the sustained release of a physiologically active agent in an animal, comprising:
dissolving a pectic substance in a carrier to give a pectic solution or dispersion, wherein the amount of the pectic substance is effective to gel in situ in the animal;
adding the physiologically active agent to the pectic solution or dispersion to give the composition.
38. The method of claim 37, wherein the carrier comprises water, saline, buffered aqueous solution, oil/water emulsion, adjuvant, tablets, or capsules.
39. The composition of claim 37, wherein the pectic substance comprises a calcium-reactive pectin.
40. The composition of claim 37, wherein the pectic substance comprises a low methoxyl pectin.
41. The method of claim 37, wherein the pectic substance comprises a polygalacturonic acid.
42. The method of claim 37, wherein the pectic substance comprises an Aloe pectin.
43. The method of claim 37 further comprising adding a monovalent cation to the composition.
44. The method of claim 37 further comprising adding a sodium salt to the composition.
45. The method of claim 37, wherein the composition has a pH of from about 2 to about 10.
46. The method of claim 37 further comprising adding a thickener to the composition
47. The method of claim 46, wherein the thickener comprises CMC, HPMC, collagen, gelatin, dextran, hyaluronic acid, or alginate.
48. The method of claim 37, wherein the physiologically active agent comprises a pharmacologically active substance, a therapeutic agent, a diagnostic agent, a peptide, a nucleic acid, or a protein.
49. The method of claim 37, wherein, based on the total weight of the composition, the physiologically active agent ranges from about 0.01 % to about 90 %.
50. A method for preparing a relatively dry composition for the sustained release of a physiologically active agent in an animal, comprising:
dissolving a mixture of a pectic substance and a physiologically active agent in a carrier to give a solution of dispersion, wherein the amount of the pectic substance is effective to gel in situ in the animal;
removing volatile components in the carrier to give the relatively dry composition.
51. The method of claim 50, wherein the carrier comprises water, saline, buffered aqueous solution, oil/water emulsion, adjuvant, tablets, or capsules.
52. The method of claim 50, wherein the pectic substance comprises a calcium-reactive pectin.
53. The method of claim 50, wherein the pectic substance comprises a low methoxyl pectin.
54. The method of claim 50, wherein the pectic substance comprises a polygalacturonic acid
55. The method of claim 50, wherein the pectic substance comprises an Aloe pectin.
56. The method of claim 50 further comprising adding a monovalent cation to the solution or dispersion.
57. The method of claim 50 further comprising adding a sodium salt to the solution or dispersion.
58. The method of claim 50 further comprising adding a thickener to the solution or dispersion.
59. The method of claim 58, wherein the thickener comprises CMC, HPMC, collagen, gelatin, dextran, hyaluronic acid, or alginate.
60. The method of claim 50, wherein the physiologically active agent comprises a pharmacologically active substance, a therapeutic agent, a diagnostic agent, a peptide, a nucleic acid, or a protein.
61. The method of claim 50, wherein, based on the total weight of the composition, the physiologically active agent ranges from about 0.01 % to about 90 %.
62. The method of claim 50, wherein the step of removing volatile components of the carrier comprises evaporation.
63. A method for sustained releasing a physiologically active agent in an animal, comprising:
dissolving a pectic substance in a carrier to give a pectic solution or dispersion, wherein the amount of the pectic substance is effective to gel in situ in the animal;
adding the physiologically active agent to pectic solution or dispersion to give a composition;
administering the composition to the animal.
64. The method of claim 63, wherein the carrier comprises water, saline, buffered aqueous solution, oil/water emulsion, adjuvant, tablets, or capsules.
65. The method of claim 63, wherein the pectic substance comprises a calcium-reactive pectin.
66. The method of claim 63, wherein the pectic substance comprises a low methoxyl pectin.
67. The method of claim 63, wherein the pectic substance comprises a polygalacturonic acid.
68. The method of claim 63, wherein the pectic substance comprises an Aloe pectin.
69. The method of claim 63 further comprising adding a monovalent ration to the composition.
70. The method of claim 63 further comprising adding a sodium salt to the composition.
71. The method of claim 63, wherein the composition has a pH of from about 2 to about 10.
72. The method of claim 63 further comprising adding a thickener to the composition
73. The method of claim 72, wherein the thickener comprises CMC, HPMC, collagen, gelatin, dextran, hyaluronic acid, or alginate.
74. The method of claim 63, wherein the physiologically active agent comprises a pharmacologically active substance, a therapeutic agent, a diagnostic agent, a peptide, a nucleic acid, or a protein.
75. The method of claim 63, wherein, based on the total weight of the composition, the physiologically active agent ranges from about 0.01 % to about 90 %.
CA 2439570 2001-02-28 2002-02-27 In-situ gel formation of pectins Active CA2439570C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/795,897 2001-02-28
US09795897 US6777000B2 (en) 2001-02-28 2001-02-28 In-situ gel formation of pectin
PCT/US2002/005974 WO2002067897A3 (en) 2001-02-28 2002-02-27 In-situ gel formation of pectins

Publications (2)

Publication Number Publication Date
CA2439570A1 true true CA2439570A1 (en) 2002-09-06
CA2439570C CA2439570C (en) 2012-04-24

Family

ID=25166729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2439570 Active CA2439570C (en) 2001-02-28 2002-02-27 In-situ gel formation of pectins

Country Status (7)

Country Link
US (1) US6777000B2 (en)
JP (2) JP2005506284A (en)
KR (1) KR20030088440A (en)
CN (1) CN1256080C (en)
CA (1) CA2439570C (en)
EP (1) EP1372606A2 (en)
WO (1) WO2002067897A3 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6702744B2 (en) 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
CN100478026C (en) * 2001-09-28 2009-04-15 纽特休迪克斯公司 Delivery system for biological component
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US7407672B2 (en) * 2002-11-04 2008-08-05 National Heart Center Composition derived from biological materials and method of use and preparation
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US7153536B2 (en) * 2003-04-15 2006-12-26 Welch Foods Inc., A Cooperative Method for preparation of a food sauce
US20040208975A1 (en) * 2003-04-15 2004-10-21 Kuhns Barbara Ann Method for preparation of a food sauce
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
EP1682132A1 (en) * 2003-09-18 2006-07-26 Macusight, Inc. Transscleral delivery
US7909809B2 (en) * 2004-09-27 2011-03-22 Boston Scientific Scimed, Inc. Devices and methods for agent-assisted medical procedures
CN100425233C (en) 2005-01-12 2008-10-15 复旦大学 Nimodipine gel for nasal cavity
EP3025713A1 (en) 2005-02-09 2016-06-01 Santen Pharmaceutical Co., Ltd Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008533204A (en) * 2005-03-21 2008-08-21 マクサイト, インコーポレイテッド Drug delivery system for the treatment of a disease or condition
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
WO2007092620A3 (en) 2006-02-09 2009-03-26 Macusight Inc Stable formulations, and methods of their preparation and use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
EP2115066A1 (en) * 2006-11-28 2009-11-11 Facultes Universitaires Notre-Dame de la Paix Composition comprising oligogalacturonans and polycationic saccharides
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
JP5693218B2 (en) * 2007-05-11 2015-04-01 アロエバイオティクス・リサーチ・ラブズ,インコーポレイテッド Skin reinforcing aloe preparations
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20090123628A1 (en) * 2007-11-09 2009-05-14 Shinya Ikeda Low acyl gellan gels with reduced thermal hysteresis and syneresis
US7833829B2 (en) * 2008-10-28 2010-11-16 Honeywell International Inc. MEMS devices and methods of assembling micro electromechanical systems (MEMS)
US8409606B2 (en) * 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
US20110129574A1 (en) * 2009-11-30 2011-06-02 Pathak Chandrashekhar P Methods and compositions for filling fleshy fruits and vegetables
US9439958B2 (en) 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
EP3195858A1 (en) 2010-04-03 2017-07-26 Praful Doshi Medical devices including medicaments and methods of making and using same
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US8592575B2 (en) 2011-06-06 2013-11-26 Cp Kelco Aps Process for extraction of pectin
US20130096552A1 (en) * 2011-10-14 2013-04-18 Christopher L. Brace Hydrodissection Material with Reduced Migration
WO2016168179A1 (en) * 2015-04-13 2016-10-20 Capsulent Succulent extract and alginate combined solutions and products incorporating them

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (en) * 1973-04-09 1983-07-05 Takeda Chemical Industries Ltd
GB1508993A (en) * 1974-04-18 1978-04-26 Mars Ltd Food product and method
US3982003A (en) 1974-09-04 1976-09-21 Mars Limited Gelling and thickening agents
CA1113393A (en) * 1978-02-24 1981-12-01 Janos Plachy Solid oral pharmaceutical product with increased efficacy and predetermined steady state of solubility
US4305933A (en) 1980-03-10 1981-12-15 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4500510A (en) 1982-09-29 1985-02-19 Aquarium Pharmaceuticals, Inc. Damaged fish tissue treating method and composition containing Aloe vera extract
JPS6237016B2 (en) 1983-03-09 1987-08-10 Teijin Ltd
US4529613A (en) * 1983-09-29 1985-07-16 General Foods Corporation Pectin-based clouding agent
JPH0157087B2 (en) * 1983-11-04 1989-12-04 Takeda Chemical Industries Ltd
DE3583799D1 (en) * 1985-01-11 1991-09-19 Abbott Lab Ltd Solid preparation with slow release.
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4917890A (en) * 1985-06-28 1990-04-17 Carrington Laboratories, Inc. Processes for preparation of aloe products, products produced thereby and compositions thereof
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
DE3601132A1 (en) 1986-01-16 1987-07-23 Christian Bannert A method for the treatment of mucosa
US4725438A (en) * 1986-05-29 1988-02-16 Leazer Billie S Aloe vera ointment
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
DE3726797A1 (en) * 1987-08-12 1989-02-23 Bayer Ag Pharmaceuticals for the field of human mouth
US5059189A (en) 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5438076A (en) * 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
US5599551A (en) * 1989-06-06 1997-02-04 Kelly; Patrick D. Genital lubricants containing zinc as an anti-viral agent
US5545673A (en) * 1989-06-06 1996-08-13 Kelly; Patrick D. Method for reducing risk of infection by sexually transmitted viruses
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
JP2911496B2 (en) * 1989-09-11 1999-06-23 帝國製薬株式会社 Physiologically active polypeptide-containing superabsorbent vaginal agent
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5284659A (en) * 1990-03-30 1994-02-08 Cherukuri Subraman R Encapsulated flavor with bioadhesive character in pressed mints and confections
US5525634B1 (en) * 1990-05-04 2000-01-18 Perio Prod Ltd Colonic drug delivery system
EP0610178B1 (en) * 1990-07-04 1996-11-13 Pharmacia AB Therapeutical composition and process for its preparation
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
KR930006431B1 (en) 1990-10-11 1993-07-16 채영복 Microcapsulation of drugs
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US6033712A (en) * 1994-05-13 2000-03-07 Ei Du Pont De Nemours And Company Gel production from plant matter
US5266318A (en) 1991-12-09 1993-11-30 Royale Renaissance, Inc. Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed
JP3802555B2 (en) 1991-12-17 2006-07-26 フイズ テクノロジーズ リミテッド Ulcer prevention and treatment compositions and methods
US5578307A (en) 1992-01-17 1996-11-26 Alfatec-Pharma Gmbh Shaped articles containing plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
US5645827A (en) * 1992-09-30 1997-07-08 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
US5400510A (en) * 1993-12-20 1995-03-28 Glodowski; Michael J. Windshield glass knife brace
US5435997A (en) * 1994-02-08 1995-07-25 Burns; Michael J. Topical agent and method for the treatment of pseudofolliculitis barbae
US5503822A (en) * 1994-04-01 1996-04-02 Schulman; Jerome M. Medicated gel
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US5674495A (en) 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
EP0817620B1 (en) * 1995-03-28 2002-01-30 Fidia Advanced Biopolymers, S.R.L. Nanospheres comprising a biocompatible polysaccharide
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
JP3098401B2 (en) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 For nasal administration formulation
GB9514438D0 (en) * 1995-07-14 1995-09-13 Danisco Stabilisation process and an enzyme for use in such a process
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
US5902796A (en) * 1995-09-22 1999-05-11 Carrington Laboratories, Inc. Bioactive factors of aloe vera plants
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5760102A (en) * 1996-02-20 1998-06-02 Carrington Laboratories, Inc. Uses of denture adhesive containing aloe extract
EP0893992B1 (en) * 1996-04-16 2004-03-03 Novartis Consumer Health S.A. Fast disintegrating oral dosage form
DK0928207T4 (en) * 1996-07-10 2008-05-05 Coloplast As The adhesive and the use of this agent
DE69704712D1 (en) 1996-08-29 2001-06-07 Sanofi Synthelabo Controlled release tablet of alfuzosin hydrochloride
JP3020141B2 (en) 1996-10-07 2000-03-15 康雄 小坂 For nasal administration formulation
CA2267116A1 (en) * 1996-10-09 1998-04-16 Givaudan-Roure (International) S.A. Process for preparing beads as food additive
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US5874094A (en) * 1997-08-05 1999-02-23 Costello; Jeremiah Cream formulation for topical application
KR20070116291A (en) * 1997-08-22 2007-12-07 스미스클라인 비참 코포레이션 Rapidly disintegrating methylcellulose tablets
DE69833000D1 (en) * 1997-09-26 2006-02-02 Noven Pharma Biological glue and process for topical administration of active ingredients
WO1999019505A1 (en) 1997-10-10 1999-04-22 Univera Pharmaceuticals, Inc. Process for the preparation of immunomodulatory polysaccharides from aloe
JPH11116935A (en) 1997-10-16 1999-04-27 Susumu Kawashima Preparation of gel by using calcium pantothenate
JP4234803B2 (en) * 1997-10-27 2009-03-04 久光製薬株式会社 Pharmaceutical compositions in which the drug release rate is controlled
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US6383495B1 (en) * 1997-12-08 2002-05-07 Council Of Scientific & Industrial Research Herbal formulation useful for treatment of skin disorders
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6284273B1 (en) 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6290964B1 (en) 1998-03-06 2001-09-18 Kathleen Shupe Antimicrobial agents isolated from aloe vera
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6313103B1 (en) * 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6033651A (en) 1998-06-10 2000-03-07 Revlon Consumer Products Corporation Gel cosmetic compositions
KR20000011247A (en) * 1998-07-23 2000-02-25 김윤 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
US6063915A (en) * 1998-07-30 2000-05-16 Hercules Incorporated Carrageenan compositions and methods for their production
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
DE60030418D1 (en) * 1999-03-17 2006-10-12 Coloplast As Pressure-sensitive adhesive composition
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6309675B1 (en) 1999-07-21 2001-10-30 Nancy Laning Sobczak Therapeutic composition including plantain and aloe vera for treatment of arthritis and other afflictions
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2003024427A1 (en) * 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
WO2001052818A1 (en) * 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
US6228387B1 (en) * 2000-01-27 2001-05-08 Murray Borod Integrated comprehensive hemorrhoid treatment compositions and regimen
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
JP4711520B2 (en) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 Physiologically active peptide-containing powder
US6368639B1 (en) * 2000-03-24 2002-04-09 Council Of Scientific And Industrial Research Herbal skin care formulation and a process for the preparation thereof
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US6365200B1 (en) * 2000-07-19 2002-04-02 Jason C. Birnholz Topical skin sensitizer
DK1320387T3 (en) * 2000-09-13 2012-07-16 Glaxosmithkline Llc Pharmaceutical compositions for the sustained release of peptides
US6596297B2 (en) * 2000-10-30 2003-07-22 New York Blood Center, Inc. Biodegradable microbicidal vaginal barrier device
US6896906B2 (en) 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
US6475526B1 (en) 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use

Also Published As

Publication number Publication date Type
EP1372606A2 (en) 2004-01-02 application
US20020119941A1 (en) 2002-08-29 application
CA2439570C (en) 2012-04-24 grant
CN1256080C (en) 2006-05-17 grant
WO2002067897A3 (en) 2003-05-01 application
KR20030088440A (en) 2003-11-19 application
WO2002067897A2 (en) 2002-09-06 application
US6777000B2 (en) 2004-08-17 grant
JP2009029824A (en) 2009-02-12 application
JP2005506284A (en) 2005-03-03 application
CN1531419A (en) 2004-09-22 application

Similar Documents

Publication Publication Date Title
US6103266A (en) Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US7579019B2 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Boddupalli et al. Mucoadhesive drug delivery system: An overview
US5133974A (en) Extended release pharmaceutical formulations
US5989535A (en) Polymeric bioadhesive emulsions and suspensions and methods of treatment
US6319510B1 (en) Gum pad for delivery of medication to mucosal tissues
US5897858A (en) Nasal spray compositions exhibiting increased retention in the nasal cavity
US20020168404A1 (en) Use of an acrylic type polymer as disintegrating agent
US20060216352A1 (en) Rapid-acting pharmaceutical composition
Nafee et al. Mucoadhesive delivery systems. I. Evaluation of mucoadhesive polymers for buccal tablet formulation
Pavelić et al. Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis
US20100239662A1 (en) Misuse preventative, controlled release formulation
US20050118217A1 (en) Rapidly disintegrating films for delivery of pharmaceutical of cosmetic agents
Bruschi et al. Oral bioadhesive drug delivery systems
WO2008068471A1 (en) New non-abusable pharmaceutical composition comprising opioids
US20070218114A1 (en) Soluble Strip for Oral or Topical Administration
US20080254105A1 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
WO2004039383A1 (en) Remedy for fibromyalgia
WO2000047233A1 (en) Tablets quickly disintegrated in the oral cavity
WO2005018323A1 (en) Edible films for administration of medicaments to animals
US20070286900A1 (en) Low dose tablets of opioid analgesics and preparation process
Varshosaz et al. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets
WO2008025791A1 (en) Buprenophine-wafer for drug substitution therapy
WO2006103418A1 (en) New pharmaceutical compositions useful in the treatment of pain
Acarturk Mucoadhesive vaginal drug delivery systems

Legal Events

Date Code Title Description
EEER Examination request